Response of plasmodium vivax malaria induced thrombocytopenia to antimalarial treatment

J Ayub Med Coll Abbottabad. 2014 Oct-Dec;26(4):463-5.

Abstract

Background: Thrombocytopenia is often seen in the patients of malaria infected with Plasmodium vivax. We studied patients admitted in hospital having coexisting thrombocytopenia and malaria, and recorded the response to anti-malarial therapy.

Methods: In this cross-sectional descriptive study, a total of 120 patients admitted in medical ward with Plasmodium vivax malaria and co-existing thrombocytopenia were studied.

Results: Out of total 120 slide positive Malaria patients who had low platelet count (<150x10(9) /L), platelet count increased to ≥150x10(9) /L in 73 (60.8%) patients after five days of anti-malarial therapy while in 47 (39.2%) patients thrombocytopenia persisted. After ten days of anti-malarial therapy, platelet count in all the patients recovered to ≥ 150x10(9) L. None of the patients required platelet transfusion.

Conclusion: In majority of the patients of Plasmodium vivax malaria having thrombocytopenia, platelet count returns to normal within five to ten days of start of anti-malarial treatment and nlatelet transfusion is not required.

MeSH terms

  • Adolescent
  • Adult
  • Antimalarials / therapeutic use*
  • Chloroquine / therapeutic use*
  • Cross-Sectional Studies
  • Female
  • Humans
  • Malaria, Vivax / complications*
  • Malaria, Vivax / drug therapy*
  • Male
  • Middle Aged
  • Platelet Count
  • Platelet Transfusion
  • Thrombocytopenia / blood
  • Thrombocytopenia / complications*
  • Thrombocytopenia / drug therapy*
  • Time Factors
  • Young Adult

Substances

  • Antimalarials
  • Chloroquine